D. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin rebound to around 70%, underscoring operational resilience and efficiency improvements, the analyst tells investors in a research note. D. Boral believes the results highlight CytoSorbents’ strong execution and the growing demand for CytoSorb, its flagship product. The firm keeps a Buy rating on the shares with a $10 price target
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTSO:
- CytoSorbents sees Q4 product revenue $9M-$9.2M vs. $7.35M last year
- Cytosorbents Initiates Rights Offering to Raise Capital
- CytoSorbents commences Rights Offering
- Cytosorbents Announces Rights Offering for Stockholders
- CytoSorbents announces details of Rights Offering
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
